HIV pre-exposure prophylaxis in men who have sex with men and transgender women: A secondary analysis of a phase 3 randomised controlled efficacy trial

The Lancet Infectious Diseases

Volumn 14, Issue 6, 2014, Pages 468-475

  Buchbinder, Susan P ^a,b   Glidden, David V ^b   Liu, Albert Y ^a,b   McMahan, Vanessa ^d   Guanira, Juan V ^e   Mayer, Kenneth H ^f,g,h   Goicochea, Pedro ^d   Grant, Robert M ^c,d  

^a SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d GLADSTONE INSTITUTE OF VIROLOGY AND IMMUNOLOGY   (United States)

^e Investigaciones Medicas en Salud   (Peru)

^f Fenway Community Health   (United States)

^g BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^h HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COCAINE; EMTRICITABINE; PLACEBO; TENOFOVIR DISOPROXIL;

ADULT; ANAL INTERCOURSE; ARTICLE; BRAZIL; COHORT ANALYSIS; CONDOM; CONTROLLED STUDY; DEMOGRAPHY; ECUADOR; FOLLOW UP; HIGH RISK BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEN WHO HAVE SEX WITH MEN; PERU; PHASE 3 CLINICAL TRIAL; PILL; PRE EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SECONDARY ANALYSIS; SELF REPORT; SEROCONVERSION; SEXUALLY TRANSMITTED DISEASE; SOUTH AFRICA; THAILAND; TRANSGENDERISM; UNITED STATES;

ADENINE; ADOLESCENT; ADULT; ANTIVIRAL AGENTS; CONDOMS; DEOXYCYTIDINE; FEMALE; HIV INFECTIONS; HIV SEROPOSITIVITY; HOMOSEXUALITY, MALE; HUMANS; MALE; PHOSPHOROUS ACIDS; SEXUAL PARTNERS; SEXUALLY TRANSMITTED DISEASES; SOUTH AFRICA; SOUTH AMERICA; THAILAND; TRANSGENDERED PERSONS; UNITED STATES; YOUNG ADULT;

EID: 84900988374     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(14)70025-8     Document Type: Article

References (38)

1. Prejean J, Song R, Hernandez A, et al. Estimated HIV incidence in the United States, 2006-2009. PLoS One 2011, 6:e17502.
2. Beyrer C, Baral SD, van Griensven F, et al. Global epidemiology of HIV infection in men who have sex with men. Lancet 2012, 380:367-377.
3. Phillips AN, Cambiano V, Nakagawa F, et al. Increased HIV incidence in men who have sex with men despite high levels of ART-induced viral suppression: analysis of an extensively documented epidemic. PLoS One 2013, 8:e55312.
4. Feigin A, El-Hayek C, Hellard M, et al. Increases in newly acquired HIV infections in Victoria, Australia: epidemiological evidence of successful prevention?. Sex Health 2013, 10:166-170.
5. Birrell PJ, Gill ON, Delpech VC, et al. HIV incidence in men who have sex with men in England and Wales 2001-10: a nationwide population study. Lancet Infect Dis 2013, 13:313-318.
6. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010, 363:2587-2599.
7. Smith D, Herbst JH, Zhang X, Rose C. Condom efficacy by consistency of use among MSM. Conference on Retroviruses and Opportunistic Infections; Atlanta, GA, USA; March 3-6, 2013. Abstract 32.
8. Grant R, McMahan V, Liu A, et al. Completed observation of the randomized placebo-controlled phase of iPrEx: daily oral FTC/TDF pre-exposure HIV prophylaxis among men and trans women who have sex with men. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention; Rome, Italy; July 17-20, 2011. Abstract WELBC04.
9. Anderson PL, Glidden DV, Liu A, et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med 2012, 4:151ra125.
10. Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR Morb Mortal Wkly Rep 2011, 60:65-68. Centers for Disease Control and Prevention (CDC).
11. Guidance on pre-exposure oral prophylaxis (PrEP) for serodiscordant couples, men and transgender women who have sex with men at high risk of HIV: recommendations for use in the context of demonstration projects 2012, WHO, World Health Organization, Geneva.
12. Krakower D, Mayer KH Engaging healthcare providers to implement HIV pre-exposure prophylaxis. Curr Opin HIV AIDS 2012, 7:593-599.
13. Tellalian D, Maznavi K, Bredeek UF, Hardy WD Pre-exposure prophylaxis (PrEP) for HIV infection: results of a survey of HIV healthcare providers evaluating their knowledge, attitudes, and prescribing practices. AIDS Patient Care STDS 2013, 27:553-559.
14. Arnold EA, Hazelton P, Lane T, et al. A qualitative study of provider thoughts on implementing pre-exposure prophylaxis (PrEP) in clinical settings to prevent HIV infection. PLoS One 2012, 7:e40603.
15. Gomez GB, Borquez A, Case KK, Wheelock A, Vassall A, Hankins C The cost and impact of scaling up pre-exposure prophylaxis for HIV prevention: a systematic review of cost-effectiveness modelling studies. PLoS Med 2013, 10:e1001401.
16. Schackman BR, Eggman AA Cost-effectiveness of pre-exposure prophylaxis for HIV: a review. Curr Opin HIV AIDS 2012, 7:587-592.
17. Paltiel AD, Freedberg KA, Scott CA, et al. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis 2009, 48:806-815.
18. Desai K, Sansom SL, Ackers ML, et al. Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness. AIDS 2008, 22:1829-1839.
19. Juusola JL, Brandeau ML, Owens DK, Bendavid E The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men. Ann Intern Med 2012, 156:541-550.
20. Guy RJ, Wand H, Wilson DP, et al. Using population attributable risk to choose HIV prevention strategies in men who have sex with men. BMC Public Health 2011, 11:247.
21. Buchbinder SP, Vittinghoff E, Heagerty PJ, et al. Sexual risk, nitrite inhalant use, and lack of circumcision associated with HIV seroconversion in men who have sex with men in the United States. J Acquir Immune Defic Syndr 2005, 39:82-89.
22. Koblin BA, Husnik MJ, Colfax G, et al. Risk factors for HIV infection among men who have sex with men. AIDS 2006, 20:731-739.
23. Rockhill B, Newman B, Weinberg C Use and misuse of population attributable fractions. Am J Public Health 1998, 88:15-19.
24. Altman DG, Andersen PK Calculating the number needed to treat for trials where the outcome is time to an event. BMJ 1999, 319:1492-1495.
25. Vallabhaneni S, Li X, Vittinghoff E, Donnell D, Pilcher CD, Buchbinder SP Seroadaptive practices: association with HIV acquisition among HIV-negative men who have sex with men. PLoS One 2012, 7:e45718.
26. Murnane PM, Celum C, Mugo N, et al. Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals: subgroup analyses from a randomized trial. AIDS 2013, 27:2155-2160. for the Partners PrEP Study Team.
27. Golden MR, Stekler J, Hughes JP, Wood RW HIV serosorting in men who have sex with men: is it safe?. J Acquir Immune Defic Syndr 2008, 49:212-218.
28. Goodreau SM, Carnegie NB, Vittinghoff E, et al. What drives the US and Peruvian HIV epidemics in men who have sex with men (MSM)?. PLoS One 2012, 7:e50522.
29. Baggaley RF, White RG, Boily MC HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV prevention. Int J Epidemiol 2010, 39:1048-1063.
30. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011, 365:493-505.
31. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012, 367:399-410.
32. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012, 367:411-422.
33. Liu AY, Vittinghoff E, Sellmeyer DE, et al. Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco. PLoS One 2011, 6:e23688.
34. Peterson L, Taylor D, Roddy R, et al. Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial. PLoS Clin Trials 2007, 2:e27.
35. Guyatt GH, Oxman AD, Kunz R, et al. What is "quality of evidence" and why is it important to clinicians?. BMJ 2008, 336:995-998.
36. Venter F, Allais L, Richter M Exposure ethics: does HIV pre-exposure prophylaxis raise ethical problems for the health care provider and policy maker?. Bioethics 2013, published online June 24. 10.1111/bioe.12021.
37. Gilmore HJ, Liu A, Koester KA, et al. Participant experiences and facilitators and barriers to pill use among men who have sex with men in the iPrEx pre-exposure prophylaxis trial in San Francisco. AIDS Patient Care STDS 2013, 27:560-566.
38. Global Advocacy for HIV Prevention. Ongoing PrEP trials AVAC, (accessed Jan 31, 2014). http://data.avac.org/OngoingPrEPTrials.aspx.